RDIF and Sanofi to develop digital healthcare solutions in Russia
Saint-Petersburg, June 4, 2021 – The Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund) and Sanofi, one of the leading global pharmaceutical companies, agree to cooperate for joint implementation of digital healthcare projects in Russia.
The corresponding announcement was made today on the sidelines of St. Petersburg International Economic Forum.
Sanofi and RDIF are planning to engage in development, maintenance, management and commercialization of Virtual Healthcare products in Russia in four therapeutic areas, including hypertension and diabetes. The products include a range of Sanofi’s initiatives, such as combination of drug therapy and technology, standalone digital therapeutics and tech-enabled virtual healthcare (virtual clinics, telehealth and wearables).
The agreement is part of RDIF’s strategy of promoting the leading healthcare technologies in Russia within the framework of RDIF.Healthcare division aiming to develop existing initiatives and launching new investment projects. Thanks to wide international network of partners and accumulated internal expertise, RDIF is implementing a number of leading anti-COVID projects in Russia and globally and is now joining efforts with Sanofi to develop new cutting-edge healthcare solutions in the future.
Kirill Dmitriev, CEO of the Russian Direct Investment Fund, said:
“Partnership with Sanofi and promotion of digital solutions in healthcare will make an important contribution for achieving goals set out in Russia’s national projects ‘Healthcare” and “Digital Economy”. Both RDIF and Sanofi strive to increase availability of quality medical aid and implement innovative digital services in healthcare. We expect this partnership to significantly change the landscape in the Russian healthcare market in the future.”
Oxana Monge, General Manager, Sanofi Eurasia, said:
“The Russian Government has set a very ambitious and noble goal to ensure that the population of Russia lives longer and healthier lives. We believe that this initiative together with RDIF is a great step forward to contribute to harnessing non-communicable chronic diseases by promoting digital and integrated solutions in the Russian healthcare market. Our mission is to reverse course of the chronic diseases. We hope that by engaging the power of technology and digital innovation to develop simplified, tailored care solutions it will be possible transform the management of such chronic diseases as diabetes and cardiovascular, thus ensuring the quality and life expectancy of the Russian patients”.
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB 2tn and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at www.rdif.ru
Sanofi is a global biopharmaceutical company whose mission is to provide support to those who face various health problems. With our vaccines, we strive to protect people from disease, and our drugs help to ease the course of many diseases and improve the quality of life of both patients with rare and common chronic diseases. More than 100 thousand Sanofi employees in 100 countries work every day to turn scientific innovations into concrete solutions in the field of health care.
For additional information contact:
Russian Direct Investment Fund
Director for External Communications
Mobile: +7 915 312 76 65
Andrew Leach / Maria Shiryaevskaya
Tel: +44 (0) 20 7796 4133
Department for Communications